Drug intelligence / Profile preview

Biotron RSV viroporin inhibitor

Development stage: Preclinical
Lead developer: Biotron Technologies
Modality: Small Molecules

Overview

Biotron is developing small molecule inhibitors that target the viroporin proteins of the Respiratory Syncytial Virus (RSV). Viroporins, such as the RSV Small Hydrophobic (SH) protein, are viral proteins that oligomerize to form ion channels in host cell membranes, which are essential for viral replication, assembly, and release. By blocking these channels, Biotron's compounds aim to inhibit the viral life cycle and provide a therapeutic option for RSV infections. The program is currently in the preclinical stage of development.

Other names: Biotron RSV programRSV viroporin-targeting small molecules

Targets

RSV SH (Respiratory syncytial virus small hydrophobic protein)

Beyond the preview

Go deeper on Biotron RSV viroporin inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotron RSV viroporin inhibitor.

Explore the full profile